By using anti-TREM2 monoclonal antibody treatment, tumor growth can be inhibited and a strong anti-tumor immune effect can be produced, which enhances the activation function of CD8+ TIL and anti-PD-1 immunotherapeutic response (15). This evidence concerns the gene CD8A and neoplasm.